Organovo Holdings | 10-K: Annual report

SEC announcementMay 31 16:10 ET · Announcements

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy With Tofacitinib for Inflammatory Bowel Disease

SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including

GlobeNewswireMay 21 08:05 ET

Express News | Organovo Granted U.S. Patent #11982668: Use Of Engineered Renal Tissues In Assays

BenzingaMay 14 12:56 ET

Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including

GlobeNewswireMay 14 11:00 ET

Express News | Organovo Holdings Shares Are Trading Lower After the Company Announced the Pricing of a $5.25 Million Public Offering of 6,562,500 Shares and Common Warrants

BenzingaMay 9 08:20 ET

Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

Shares of AppLovin Corporation (NASDAQ:APP) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results.The company posted revenue of $1.

BenzingaMay 9 08:13 ET